Axsome Therapeutics has a one year low of $64.11 and a one year high of $113.33. The firm has a market cap of $5.47 billion, a P/E ratio of -17.29 and a beta of 1.05.

Baird analyst Joel Beatty raised the firm’s price target on Axsome Therapeutics (AXSM) to $132 from $116 and keeps an Outperform rating on the shares. The firm said the approval of AXS-07 shifts ...

Truist analyst Joon Lee raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $180 and keeps a Buy rating on the shares. The company disclosed approval of Symbravo – AXS-07 ...

Axsome Therapeutics has finally jumped all the hurdles in a challenging regulatory saga, winning approval for its oral migraine drug Symbravo. The rapid-acting treatment is approved for the acute ...

This news article is based on a press release statement from Axsome Therapeutics (NASDAQ:AXSM). The company continues to focus on addressing critical gaps in CNS treatment and advancing patient ...

NASDAQ AXSM opened at $106.46 on Wednesday. Axsome Therapeutics has a one year low of $64.11 and a one year high of $111.51. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 ...

Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Axsome Therapeutics' (AXSM.O), opens new tab migraine treatment, the company said on Thursday. The oral drug, branded Symbravo ...